Sign up for free psoriasis treatment tips by email.

EMAIL ADDRESS:


Find us on Facebook




Latest News

SEE ALLOur Sponsors




Secukinumab (AIN457)

BRAND NAME: n/a
GENERIC NAME: secukinumab
EXPERIMENTAL/INTERNAL COMPANY NAME: AIN457
TESTING PHASE
II


DRUG USE (P OR PsA)METHOD OF DELIVERYDEVELOPING COMPANY/COMPANIES
Psoriasis and psoriatic arthritisInjection under the skin, or intravenous infusionNovartis Pharmaceuticals


Description and Comments

Secukinumab (AIN457) is a fully human antibody to Interleukin-17A (IL-17A), which is a protein/cytokine with inflammatory properties.  The goal of secukinumab is to neutralize IL-17A, reducing inflammation and hopefully improving symptoms in psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), uveitis (inflammation of the eye), Crohn’s disease and perhaps other diseases.


Secukinumab (AIN457) is currently in Phase Two clinical trials in psoriasis, psoriatic arthritis and other diseases.  In one small trial, intravenous infusion of secukinumab reduced psoriasis symptoms, as well as symptoms of RA and uveitis.  This has encouraged Novartis to expand its trials, with the hopes of reaching market for uveitis as soon as 2012, with psoriasis and psoriatic arthritis expected some time after that.


With current psoriasis biologics targeting TNF-alpha and IL-12 and IL-23, secukinumab reflects a novel target, IL-17A, which would offer an exciting new approach for psoriasis patients, and one that could theoretically work even for those who have not found relief from existing treatments.

Other News and Links

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis, Science Translational Medicine article, October 2010

 

Experimental Novartis drug helps range of diseases, Reuters, October 6, 2010

© 2005-2014 Psoriasis Cure Now WEB DESIGN BY SKYHOOK MARKETING